{"name":"Avenzo Therapeutics, Inc.","slug":"avenzo-therapeutics-inc","ticker":"","exchange":"","domain":"avenzo.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"AVZO-021","genericName":"AVZO-021","slug":"avzo-021","indication":"Other","status":"phase_1"},{"name":"AVZO-023","genericName":"AVZO-023","slug":"avzo-023","indication":"Other","status":"phase_1"},{"name":"AVZO-103","genericName":"AVZO-103","slug":"avzo-103","indication":"Other","status":"phase_1"},{"name":"AVZO-1418","genericName":"AVZO-1418","slug":"avzo-1418","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AVZO-021","genericName":"AVZO-021","slug":"avzo-021","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVZO-023","genericName":"AVZO-023","slug":"avzo-023","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVZO-103","genericName":"AVZO-103","slug":"avzo-103","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVZO-1418","genericName":"AVZO-1418","slug":"avzo-1418","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2025-11-24","type":"pipeline","source":"Business Wire","summary":"Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previo","headline":"Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Anti","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-10","type":"pipeline","source":"Business Wire","summary":"Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated","headline":"Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNbU9rVHJXRGNtT1ZaYmw0WEJHYnRmdHpicndXN0ZhUWtfclZDNTdMS3BYeWd2QXBMTndQZ3FxVnQtV2JoeHlKeVd5amFEbE9yNmF0VE85NmVpSmN4WDdBVDlKRmFfdGMzZDdqMURyNVRxUnJOV2VVdlo0UVFCSUZtNDNDbS1MT0I1Rm1oOA?oc=5","date":"2025-09-29","type":"pipeline","source":"San Diego Business Journal","summary":"Avenzo Raises $60M Series B - San Diego Business Journal","headline":"Avenzo Raises $60M Series B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxOLWdoRUszQ0g3cTdaNnFmbW9GUGcxZGozYUQ5OG1fWnVQWmV4OHlkdS1wSUxyXzc5NzBxcXRjN3RNai1wV0dwUVdaSjBCNGs1Y2paelBaSGJ4SWxkUzJGb3d3VW5ERjVhREtCU0dqRklpQjFIdi1mVllrenFtVVpTOGVaQTFVUWRIM2c2Q2xRNVdSeC1TV042dzdESE91QXJJQ3RKVG15cHQ5b3ZpMDlHVHJ4RGh1YjZaR3JUeGdYVkRwQXN1VzF2Z0dYMWh5RFhhT1EzTFpUTTl4TmhpdUh4d1FocC1jR1g5bGNwQnBtRzlaMzBqMTY4YUozWVZDS1NUOEowaTZUbjRST1dReGVNVzgxa3E4YUpabk0yWkhCSjZYQQ?oc=5","date":"2025-09-29","type":"trial","source":"Business Wire","summary":"Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Business Wire","headline":"Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific A","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQYWtIRGlZQlM2S1k1SERLejNiNzFDSjFiRUZHTnliOHFqR2ZlcE9JX2NPVHRXY3VHcFh3aFBZdExZUnU2Qm5qV1NFV1BuYVRaWXRKSEFrTUktV2VZUjNwUDZfdGgyUHAzZ2tORDdkV2Q3WDZ3SnV0UjR5eFg3MmZtUll2WGc0dUpPMmVJNE92SWlnY1YxNWl0UGcwZk1uVVBseDRGTTZIR0cwSXB4NjVwckt4S2NaSms0bDE0?oc=5","date":"2025-09-22","type":"pipeline","source":"Business Wire","summary":"Avenzo Therapeutics Announces $60 Million Series B Financing - Business Wire","headline":"Avenzo Therapeutics Announces $60 Million Series B Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBzZ2lyT3ZyVE9vNHBfLVhpRVlNN0JCX3l4YU1LUGxIZExWNm0tZldkLXRYU2dWYUpsWUpoZUFIR3Nsamh4YnRUNlgwcjVUdWpSNFNz?oc=5","date":"2025-09-22","type":"pipeline","source":"FirstWord Pharma","summary":"Avenzo, Ensoma each add over $50M to their coffers - FirstWord Pharma","headline":"Avenzo, Ensoma each add over $50M to their coffers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNZm1TLTY0bzdWTElyZHpHSDd0MDU3SWJHbmw5LWVfRDZNbFJ5Q0puV2JiVDVIbnVxZlg2eHU3bmpmYUlnNXhETldKQW51VEF5ZWdZSWJxakxBSWNFQ0FyV3N3a1lCNnE4eXdQNHRIRmtJQlAyVmtVMEpRYndWaEh1OFEwWUI3c2E5MUtpUV9ORXFTczJKSFJNNkM0Q05mVWxBVnJ4b1VsV1d3dzFkMVBzbk1SYWR0ZFU2VnR2RTI3Z1ZMTlNZNk1JRHcyQ2RoZ2I4cXYtdW5QMS00U1J2MEh0ZDc1X2hHOUtRNDJaY0tvSkFPNm1DZWxtVFlvQWdFZEs1SnlLZWVzemtZYjg2MVQwbVRIS0ZGUjVoaDhLbWR4OEt3ODZtTWtYRVNGbGk1ZHNPZ3ktSF9iYm03Tlg5RzhRemZ6YjVDQm56M2hJ?oc=5","date":"2025-09-02","type":"regulatory","source":"Business Wire","summary":"Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate - Business Wire","headline":"Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Cl","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNclp0ZVBkeGkzZDZkYzVBNV9zaXJhcTQ5c1NuaDVwMnF6RnpuQkdTZDJoM0tWYUVzNEFVendjVzRvUG1KVi1CNUpIWTJpYzhDTk5JWTg1NFhaWEtxMm85TmxNRzVZRjdOVFAwazY5TVF6ZkJzVTBkdktVcndoS1ROX3JHdnNZWkJWV3E3ajAwUTFWVlB0X2RNT185YlJrV2ptUVk1WHZVLXJZSDRaYVdldW9SYlFValJRYlowWWR0LVg1U0pPZlk3bDZEeEhIYXF3XzdfWFUzZ0FvLUxIZ3EyQkxlbHpSc1Nwam9QS2c0dw?oc=5","date":"2025-05-26","type":"regulatory","source":"BioPharma APAC","summary":"Avenzo Therapeutics and Duality Biotherapeutics Gain FDA Clearance for EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418 - BioPharma APAC","headline":"Avenzo Therapeutics and Duality Biotherapeutics Gain FDA Clearance for EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxPcG1PdElJX2EyY1l5Sjludk1xN3Y0RUtRYkVhQm1lOGFlV3lYQ3Z4UXZxSHJyOFdqS2d2dDd0dnIyLTlMWTRUd3FRUUd5czNnVlZrSEFFekt1b2l3Nm1vV3Q3TkZiS01ZeEtFZlA3STR4b1RVekhkSlkwcGxnR0tMcms3YXhTdXdQZmt4aFhib1U?oc=5","date":"2025-01-08","type":"deal","source":"The Pharma Letter","summary":"Avenzo and DualityBio ink exclusive global license deal - The Pharma Letter","headline":"Avenzo and DualityBio ink exclusive global license deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOemZ5cDVORkx2cDVlME40RFBGekg3THRqYjdqMG1yeF9UTFEyWXV0M2FhVDRVVVNMNXFsRUZWZ3VFWV9DMUhoTjZDWElkXy1ZWWFoWnRtVy0wU0lOLU5CUmx2MVdvVURWN2N0ZnREN1hxRm9tbFM2LXJlaHFKM0ZSX2pnem5iSFZL?oc=5","date":"2024-11-19","type":"pipeline","source":"The Pharma Letter","summary":"Avenzo announces updates on pipeline and finances - The Pharma Letter","headline":"Avenzo announces updates on pipeline and finances","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxPRm5HREduSEEwVGdKLWs1RzBXMEJXTXQ0TFB3M01feWltV01RbFRDMlpiZWZpY29CUFF3enhwSEphWS1sbUlzdmlOQjRJRlY1TzYyNHY0VTB2NUxVQXczTWVoNVNRZ200N2NQcmJvMVY0VEpKOW1EQ0NGYVZEdzVVUWhHMFZOYVhHVjNuWDB0M29JNjIyZkxVUHBXeVRsZnhPcWlTM19UX19wSFN5ZkRpT29yNWwtOTlrTWFHSXJicTRrOVVVRUoyeHhncWhiaS04RGJIVXptdw?oc=5","date":"2024-10-01","type":"pipeline","source":"BioSpace","summary":"Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director - BioSpace","headline":"Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPZTVaMXNWcHJneTdNWThBRUp6Y2haZnFrTzgxYUExWjMzdDlzNzBZd3NGU19oTzRWOUM0b243VWxnVkZtNDMxRHpSczRmSDlNaEUyU1BPVklzMV8yWk03U0ZQa0hRdDJEVlhLNnA2Y3hfMEE1cVdJQnNPV2RtY2wyNzF1cw?oc=5","date":"2024-03-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology","headline":"Avenzo Therapeutics secures $150m to bolster oncology pipeline","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":4},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}